Biopharmaceutical company initial public offerings appear to be getting back to their rapid 2020 pace with three IPOs launched in the US during the first week of December. Silverback Therapeutics, Inc. and Sigilon Therapeutics, Inc. went public on 3 December after Kinnate Biopharma, Inc. priced its first-time offering a day earlier. All three companies’ stock prices closed higher on their first days of trading.
Lixte Biotechnology Holdings, Inc. was the only drug developer to launch an IPO during the last week of November...